IKK

IκB kinase; I kappa B kinase

IKK is a complex composed of three subunits: IKKα, IKKβ, and IKKγ (also called NEMO). The complex is the signal integration hub for NF-κB activation. It integrates signals from all NF-κB activating stimuli to catalyze the phosphorylation of various IκB and NF-κB proteins, as well as of other substrates. The human IKK family has four members, the IKKs IKK-alpha and IKK-beta, and the IKK-related kinases TBK1 and IKK-epsilon.

Two members, IKKα and IKKβ, the so-called canonical members, phosphoryate IκBα, leading to activation of the transcription factor NF-κB, which controls the expression of many immune and inflammatory genes. The IKK-related proteins TBK-1 and IKK-epsilon have a different substrate--IRF3--which regulates a different set of genes, the products of which include Type I interferons. IKKs are a therapeutic target due to their crucial roles in various biological processes, including the immune response, the stress response, and tumor development.

IKK Inhibitors

(Rac)-BAY-985

Cat. No.: HY-133117A

(Rac)-BAY-985 (Compound Example 100.01) is a potent, ATP-competitive and selective **TBK1** inhibitor with an IC_{50} of 1.5 nM. Antitumor efficacy.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ACHP Hydrochloride

(IKK-2 Inhibitor VIII)

Cat. No.: HY-13060

ACHP Hydrochloride (IKK-2 Inhibitor VIII) is a highly potent and selective **IKK-β** inhibitor with an IC_{50} of 8.5 nM.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amlexanox

(AA673; Amoxanox; CHX3673)

Cat. No.: HY-B0713

Amlexanox (AA673; Amoxanox; CHX3673) is a specific inhibitor of **IKKε** and **TBK1**, and inhibits the IKKε and TBK1 activity determined by MBP phosphorylation with an IC_{50} of approximately 1-2 μM.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Anti-inflammatory agent 6

Cat. No.: HY-139833

Anti-inflammatory agent 6 blocks the phosphorylation of **I kappa b kinase α/β (IKKα/β)**, **IκBα**, and **nuclear factor kB p65 (NF-κB p65)** which is a key controller of inflammation, thereby showing anti-inflammatory potential.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZD3264

Cat. No.: HY-19362

AZD3264 is a selective IkB-kinase **IKK2** inhibitor.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

BAY 11-7082

(BAY 11-7821)

Cat. No.: HY-13453

BAY 11-7082 is an **IκBα phosphorylation** and **NF-κB** inhibitor. BAY 11-7082 selectively and irreversibly inhibits the TNF-α-induced phosphorylation of IκB-α, and decreases NF-κB and expression of adhesion molecules.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bay 65-1942 (R form)

Cat. No.: HY-50949A

Bay 65-1942 R form is the less active R-form of Bay 65-1942. Bay 65-1942 is an ATP-competitive and selective IKKβ inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Bay 65-1942 free base

Cat. No.: HY-50949

Bay 65-1942 free base is an ATP-competitive and selective **IKKβ** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bay 65-1942 hydrochloride

Cat. No.: HY-50948

Bay 65-1942 hydrochloride is an ATP-competitive and selective **IKKβ** inhibitor.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg

BAY-985

Cat. No.: HY-133117

BAY-985 is a highly potent, orally active and selective ATP-competitive dual inhibitor of **TBK1** and **IKKε** with IC_{50}s of 2/30 and 2 nM for TBK1 (low/high ATP) and IKKε, respectively. Antitumor efficacy.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

BI605906

Cat. No.: HY-13019

BI605906 is a novel **IKKβ** inhibitor with an IC_{50} value of 380 nM when assayed at 0.1 mM ATP.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BMS-066

Cat. No.: HY-18710

BMS-066 is an **IKKβ/Tyk2** pseudokinase inhibitor, with IC_{50}**s** of 9 nM and 72 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-345541

Cat. No.: HY-10519

BMS-345541 is a selective inhibitor of the catalytic subunits of **IKK** (**IKK-2** IC_{50}=0.3 μM, **IKK-1** IC_{50}=4 μM). BMS-345541 binds at an allosteric site of IKK.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

BMS-345541 hydrochloride

Cat. No.: HY-10518

BMS-345541 hydrochloride is a selective inhibitor of the catalytic subunits of **IKK** (**IKK-2** IC_{50}=0.3 μM, **IKK-1** IC_{50}=4 μM). BMS-345541 binds at an allosteric site of IKK.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BX795

Cat. No.: HY-10514

BX795 is a potent and selective inhibitor of **PDK1**, with an IC_{50} of 6 nM. BX795 is also a potent and relatively specific inhibitor of **TBK1** and **IKKε**, with an IC_{50} of 6 and 41 nM, respectively.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Chicanine

Cat. No.: HY-N2270

Chicanine is a lignan compound of Schisandra chinesis, inhibits LPS-induced phosphorylation of **p38 MAPK**, **ERK 1/2** and **IκB-α**, with anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Ertiprotafib

(PTP 112)

Cat. No.: HY-19383

Ertiprotafib is an inhibitor of **PTP1B**, **IkB kinase β (IKK-β)**, and a dual **PPARα and PPARβ** agonist, with an IC_{50} of 1.6 μM for PTP1B, 400 nM for IKK-β, an EC_{50} of ~1 μM for PPARα/PPARβ.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glabrescone C

Cat. No.: HY-N10112

Glabrescone C possesses potent anti-inflammatory activity by directly bnding to **IKKα/β**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

GS143

Cat. No.: HY-110261

GS143 is a selec-tive **IκBα ubiquitination** inhibitor with an IC_{50} of 5.2 μM for $SCF^{\beta TrCP1}$-mediated **IκBα ubiquitylation**. GS143 sup-presses **NF-κB** acti-va-tion and tran-scrip-tion of tar-get genes and does not inhibit proteasome activity. GS143 has anti-asthma effect.



Purity: 98.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK319347A

Cat. No.: HY-14682

GSK319347A is a dual inhibitor of **TBK1** and **IKKε** with IC_{50}**s** of 93 nM and 469 nM, respectively. GSK319347A also inhibits **IKK2** with an IC_{50} of 790 nM.



Purity: 98.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

GSK8612

Cat. No.: HY-111941

GSK8612 is a highly selective and potent **Tank-binding Kinase-1 (TBK1)** inhibitor, with a **pIC$_{50}$** of 6.8 for recombinant TBK1.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HOIPIN-1

(JTP-0819958)

Cat. No.: HY-122881

HOIPIN-1 (JTP-0819958) is a selective **linear ubiquitin chain assembly complex (LUBAC)** inhibitor with an **IC$_{50}$** of 2.8 μM. HOIPIN-1 suppress LUBAC-mediated NF-κB activation in vitro.



Purity: 97.10%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HPN-01

Cat. No.: HY-135366

HPN-01 is a potent and selective **IKK** inhibitor, with **pIC$_{50}$** values of 6.4, 7.0 and <4.8 for IKK-α, IKK-β and IKK-ε, respectively. HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2.



Purity: 98.40%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IKK 16

Cat. No.: HY-13687

IKK 16 is a selective IκB kinase (**IKK**) inhibitor for **IKK2**, **IKK complex** and **IKK1** with **IC$_{50}$**s of 40 nM, 70 nM and 200 nM, respectively. IKK16 also inhibits leucine-rich repeat kinase-2 (**LRRK2**) with an **IC$_{50}$** of 50 nM.



Purity: 99.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

IKK 16 hydrochloride

Cat. No.: HY-13687A

IKK 16 hydrochloride is a selective IκB kinase (**IKK**) inhibitor for **IKK2**, **IKK complex** and **IKK1** with **IC$_{50}$**s of 40 nM, 70 nM and 200 nM, respectively. IKK16 also inhibits leucine-rich repeat kinase-2 (**LRRK2**) with an **IC$_{50}$** of 50 nM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

IKK-IN-1

Cat. No.: HY-13873

IKK-IN-1 is an inhibitor of **IKK** extracted from patent WO2002024679A1, compound example 18-13.



Purity: 95.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

IKK-IN-3

Cat. No.: HY-136392

IKK-IN-3 is a potent and selective **IkappaB kinase 2** (**IKK2** or **IKKβ**) inhibitor, with **IC$_{50}$**s of 19 and 400 nM for IKK2 and IKK1 (or IKKα), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IKK-IN-4

Cat. No.: HY-136393

IKK-IN-4 is a potent and selective **IkappaB kinase 2** (**IKKβ** or**IKK2**) inhibitor, with **IC$_{50}$**s of 45 and 650 nM for IKKβ and IKKα, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IKKβ-IN-1

Cat. No.: HY-146723

IKKβ-IN-1 is a potent and orally active **IkappaB** (**IKK-β**) inhibitor with **IC$_{50}$** of 0.20 μM. IKKβ-IN-1 can reduce **PGE$_2$** and **TNF-α** production in mouse macrophage cells. IKKβ-IN-1 has the ability to protect mice against septic shock induced mortality.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IMD-0354

(IKK2 Inhibitor V)

Cat. No.: HY-10172

IMD-0354 (IKK2 Inhibitor V) is a selective **IKKβ** inhibitor which inhibits NF-κB activity. IMD0354 inhibits TNF-α induced NF-κB transcription activity with an **IC$_{50}$** of 1.2 uM.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

IMD-0560

Cat. No.: HY-105661

IMD-0560 is a novel **IκB kinase β** inhibitor.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

INH14

Cat. No.: HY-114454

INH14 is a cell permeable inhibitor of **IKKα/IKKβ**, with **IC_{50}**s of 8.97 and 3.59 μM, respectively. INH14 inhibits the IKKα/β-dependent **TLR** inflammatory response. INH14 also inhibits downstream of TAK1/TAB1 and NF-kB pathways. Anti-inflammatory and anti-cancer activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LY2409881

Cat. No.: HY-B0788

LY2409881 is a selective IκB kinase β (**IKK2**) inhibitor with an **IC_{50}** of 30 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

LY2409881 trihydrochloride

Cat. No.: HY-B0788A

LY2409881 trihydrochloride is a selective IκB kinase β (**IKK2**) inhibitor with an **IC_{50}** of 30 nM.



Purity: 98.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Malachite green oxalate

Cat. No.: HY-D0162

Malachite green oxalate is a triphenylmethane dye which can be used to detect the release of phosphate in enzymatic reactions. Malachite green oxalate is also a potent and selective inhibitor of **IKBKE**, and inhibits its downstream targets such as **IκBα**, **p65** and **IRF3**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

MLN120B

(ML120B)

Cat. No.: HY-15473

MLN120B (ML120B) is a potent, ATP competitive, and orally active inhibitor of **IKKβ** with an **IC_{50}** of 60 nM. MLN120B inhibits multiple myeloma cell growth in vitro and in vivo and also can be used for the research of rheumatoid arthritis.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MLN120B dihydrochloride

(ML120B dihydrochloride)

Cat. No.: HY-15473A

MLN120B dihydrochloride (ML120B dihydrochloride) is a potent, ATP competitive, and orally active inhibitor of **IKKβ** with an **IC_{50}** of 60 nM. MLN120B inhibits multiple myeloma cell growth in vitro and in vivo and also can be used for the research of rheumatoid arthritis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MRT67307

Cat. No.: HY-13018

MRT67307 is a dual inhibitor of the **IKKε** and **TBK-1** with **IC_{50}**s of 160 and 19 nM, respectively. MRT67307 also inhibits **ULK1** and **ULK2** with **IC_{50}**s of 45 and 38 nM, respectively. MRT67307 also blocks **autophagy** in cells.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MRT67307 hydrochloride

Cat. No.: HY-13018A

MRT67307 hydrochloride is a dual inhibitor of the **IKKε** and **TBK-1** with **IC_{50}**s of 160 and 19 nM, respectively. MRT67307 hydrochloride also inhibits **ULK1** and **ULK2** with **IC_{50}**s of 45 and 38 nM, respectively. MRT67307 hydrochloride also blocks **autophagy** in cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NF-κB-IN-1

Cat. No.: HY-138537

NF-κB-IN-1, a 4-arylidene crucumin analogue, is a potent **NF-κB signaling pathway** inhibitor. NF-κB-IN-1 directly inhibits **IKK** to block NF-κB activation. NF-κB-IN-1 effectively inhibits the viability of lung cancer cells and attenuates the clonogenic activity of A549 cells.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-184

Cat. No.: HY-107591

PF-184 is a potent inhibitory factor-κB kinase 2 (**IKK-2**) inhibitor with an IC_{50} of 37 nM. PF-184 has anti-inflammatory effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PHA 408

Cat. No.: HY-14180

PHA 408 (PHA-408) is a potent, selective and orally active IκB kinase-2 (IKK-2) inhibitor. PHA 408 is a powerful anti-inflammatory agent against lipopolysaccharide (LPS)- and cigarette smoke (CS)-mediated lung inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Plantainoside D

Cat. No.: HY-N5063

Plantainoside D shows **ACE** inhibitory activity with IC_{50} 2.17 mM. And plantainoside D is a promising **IKK-β** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

PS-1145

Cat. No.: HY-18008

PS-1145 is an IκB kinase (**IKK**) inhibitor with an IC_{50} of 88 nM.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Resveratrol

(trans-Resveratrol; SRT501)

Cat. No.: HY-16561

Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties.



Purity: 99.89%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg

Resveratrol analog 1

Cat. No.: HY-136203

Resveratrol analog 1 is an analog of Resveratrol (HY-16561), compound 48. Resveratrol is a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Resveratrol analog 2

Cat. No.: HY-136204

Resveratrol analog 2 is an **analog** of Resveratrol (HY-16561). Resveratrol is a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Resveratrol-13C6

(trans-Resveratrol-13C6; SRT501-13C6)

Cat. No.: HY-16561S1

Resveratrol-13C6 (trans-Resveratrol-13C6) is the 13C-labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Resveratrol-d4

(trans-Resveratrol-d4; SRT501-d4)

Cat. No.: HY-16561S

Resveratrol-d4 (trans-Resveratrol-d4) is the deuterium labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SC-514

(GK 01140)

Cat. No.: HY-13802

SC-514 is a selective **IKK-2** inhibitor (IC_{50}=11.2 μM), which does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Siegesbeckialide I

Cat. No.: HY-N10111

Siegesbeckialide I most potently inhibits LPS-induced NO production in RAW264.7 murine macrophages by directly binding to **IKKα/β**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

TBK1/IKKε-IN-1

Cat. No.: HY-U00457

TBK1/IKKε-IN-1 is a dual **TBK1** and **IKKε** inhibitor extracted from patent US20160376283 A1, Compound 274 in Example 60, has IC_{50}s of <100 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TBK1/IKKε-IN-2

Cat. No.: HY-12453

TBK1/IKKε-IN-2 is a dual **TBK1** and **IKKε** inhibitor.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TBK1/IKKε-IN-4

Cat. No.: HY-124652

TBK1/IKKε-IN-4 is a 6-aminopyrazolopyrimidine derivative and a potent, selective **TBK1** and **IKKε** inhibitor with IC_{50} values of 13 nM and 59 nM, respectively.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TBK1/IKKε-IN-5

Cat. No.: HY-128679

TBK1/IKKε-IN-5 (compound 1) is a dual **TBK1** and **IKKε** inhibitor, with IC_{50} values of 1 nM and 5.6 nM for TBK1 and IKKε, respectively.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TBK1/IKKε-IN-6

Cat. No.: HY-138931

TBK1/IKKε-IN-6 (example 110) is a **TBK1** and **IKKε** inhibitor, with IC_{50} values of <100 nM for both TBK1 and IKKε.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TPCA-1

Cat. No.: HY-10074

TPCA-1 is a potent and selective inhibitor of **IKK-2** with IC_{50} of 17.9 nM. TPCA-1 is an effective inhibitor of **STAT3** phosphorylation, DNA binding, and transactivation.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vinpocetine

(Ethyl apovincaminate)

Cat. No.: HY-13295

Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na^+ channels. The IC_{50} value of Vinpocetine on direct **IKK** inhibition in the cell-free system is 17.17 μM.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Vinpocetine-d5

Cat. No.: HY-13295S

Vinpocetine-d5 is the deuterium labeled Vinpocetine. Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na^+ channels. The IC_{50} value of Vinpocetine on direct **IKK** inhibition in the cell-free system is 17.17 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg